Vanessa Brito de Souza Rabello

Dr. Vanessa Brito de Souza Rabello

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
VRVanessa Brito de Souza Rabello
Vanessa Brito de Souza Rabello
MAMarcos Almeida
Marcos Almeida
AEAndrea Reis Bernardes Engemann
Andrea Reis Bernardes Engemann
RARodrigo Almeida-Paes
Rodrigo Almeida-Paes
Priscila Marques de MacedoPriscila Marques de Macedo
Priscila Marques de Macedo
RZRosely M. Zancopé-Oliveira
Rosely M. Zancopé-Oliveira

10 January 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Vanice Rodrigues PoesterVanice Rodrigues Poester
Vanice Rodrigues Poester
RBRossana Patricia Basso
Rossana Patricia Basso
DSDavid Stevens
David Stevens
LMLívia Silveira Munhoz
Lívia Silveira Munhoz
VRVanessa Brito de Souza Rabello
Vanessa Brito de Souza Rabello
MXMelissa Orzechowski Xavier
Melissa Orzechowski Xavier
We describe the successful treatment of a series of 30 zoonotic sporotrichosis cases from southern Brazil. Sporothrix brasiliensis was the species genotypically identified in all 25 confirmed cases. Five other cases were classified as probable, without laboratory confirmation, but with clinical and epidemiological data of cat-transmitted sporotrichosis. Two isolates were sequenced by translation elongation factor-1 alpha (EF1α) loci in order to compare their sequences, and both of them showed distinct genotypes from S. brasiliensis strains from other Brazilian states. Itraconazole (ITZ) or potassium iodide (KI) were the first choice treatment in 28 and 2 cases, respectively. Microdilution assay showed a wild-type profile of S. brasiliensis isolates to ITZ. However, a lack of clinical response occurred in 42% of cases, especially those treated with ITZ 100 mg/day, and treatment needed modifications, by either increased doses or antifungal combinations. Clinical cure required a mean of 187 days of treatment, which was dependent on the clinical form of the disease and age of patients. Therapy, including dosages and durations, for cutaneous forms of sporotrichosis requires re-evaluation, since cases caused by S. brasiliensis may influence treatment efficacy.

4 June 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
FSFernando Almeida Silva
Fernando Almeida Silva
VRVanessa Brito de Souza Rabello
Vanessa Brito de Souza Rabello
BSBruno de Souza Scramignon-Costa
Bruno de Souza Scramignon-Costa
RZRosely M. Zancopé-Oliveira
Rosely M. Zancopé-Oliveira
Priscila Marques de MacedoPriscila Marques de Macedo
Priscila Marques de Macedo
RARodrigo Almeida-Paes
Rodrigo Almeida-Paes
In Brazil, sporotrichosis has transitioned from a rural to urban disease, driven by a shift in the initiation of infection from the accidental inoculation of organic matter to the traumatic implantation of the fungus by cats. Since the emergence of zoonotic sporotrichosis caused by Sporothrix brasiliensis, investigations have largely ignored the environmental habitat of the pathogen due to its association with domestic cats. Therefore, we investigated 18 environmental samples collected from rural areas of two cities where zoonotic sporotrichosis is endemic, but where domestic cats are scarce. We utilized traditional culture methods, and samples were also examined with two molecular methods used for the clinical diagnosis of sporotrichosis: a nested-PCR targeting the ITS region and a species-specific PCR targeting the calmodulin gene. No Sporothrix colonies were identified by traditional culture methods. However, the nested-PCR and the species-specific PCR for S. brasiliensis were positive for 18 and 5 samples, respectively. Sequencing revealed that positive results with the nested-PCR were due to non-specific amplification of other Ophiostomatales DNA, rather than Sporothrix spp. Three of the five amplicons from the species-specific PCR were suitable for sequencing and confirmed the presence of S. brasiliensis DNA. Hence, we confirmed that S. brasiliensis, as with other Sporothrix species, has an environmental habitat. Our findings underscore the challenges of nested-PCR for Sporothrix environmental studies and highlight that sequencing must follow PCR protocols to definitively identify Sporothrix spp. in environmental samples.

30 March 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CVCarlos Alberto Tiburcio Valeriano
Carlos Alberto Tiburcio Valeriano
RLReginaldo Lima-Neto
Reginaldo Lima-Neto
CICícero Pinheiro Inácio
Cícero Pinheiro Inácio
VRVanessa Brito de Souza Rabello
Vanessa Brito de Souza Rabello
EOErtênia Paiva Oliveira
Ertênia Paiva Oliveira
Manoel Marques Evangelista OliveiraManoel Marques Evangelista Oliveira
Manoel Marques Evangelista Oliveira
Sporothrix chilensis is a mild-pathogenical specie of Sporothrix pallida complex, until now, known as restrict to Chile. Herein, we describe the first clinical isolates identified as S. chilensis in Brazil, preserved in the URM Culture Collection, by polyphasic taxonomy, and their respective antifungal profile of this emergent fungus. Fungi of the Sporothrix schenckii Complex are the causative agents of the sporotrichosis, subcutaneous mycosis that presents a massive global distribution. In this work, we perform a taxonomic review, by a poliphasic approach, of Sporothrix sp. isolates stored in the University of Recife Culture Collection (Micoteca URM), previously identified as Sporothrix schenckii by classic methods of taxonomic identification. In addition, we perform the method of broth microdilution, aiming to acquire the minimal inhibitory concentration of the standard antifungals (itraconazole and amphotericin B) against these isolates. By sequencing of the partial β-tub-encoding gene, we confirm the occurrence of S. schenckii, and identified four isolates as the S. pallida Complex component, S. chilensis. All the isolates were susceptible to the antifungals, except one, that shows resistance to amphotericin B. Our study demonstrated the first occurrence of S. chilensis in Brazil. Also, we provide the first data concerned the resistance profile of this specie for the choice antifungals in the sporotrichosis treatment, what will have important implications with this regard in the future.

14 July 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AAAnna Carolina Procópio de Azevedo
Anna Carolina Procópio de Azevedo
VRVanessa Brito de Souza Rabello
Vanessa Brito de Souza Rabello
MMM.M. Muniz
M.M. Muniz
MFMaria Helena Figueiredo-Carvalho
Maria Helena Figueiredo-Carvalho
RARodrigo Almeida-Paes
Rodrigo Almeida-Paes
DFDayvison Freitas
Dayvison Freitas

27 August 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JNJuliana Nahal
Juliana Nahal
RCRowena Alves Coelho
Rowena Alves Coelho
FSFernando Almeida Silva
Fernando Almeida Silva
AEAndrea Reis Bernardes Engemann
Andrea Reis Bernardes Engemann
AAAnna Carolina Procópio de Azevedo
Anna Carolina Procópio de Azevedo
MFMaria Helena Figueiredo-Carvalho
Maria Helena Figueiredo-Carvalho
Over the past two decades, zoonotic sporotrichosis transmitted by naturally infected cats has become hyperendemic in Rio de Janeiro, Brazil. Sporothrix brasiliensis is the main agent involved. However, there are other forms of transmission of sporotrichosis. The aim of this study was to evaluate and associate the epidemiological, clinical and therapeutic data and the susceptibility of Sporothrix spp. to antifungal drugs in 43 non-zoonotic sporotrichosis cases. Forty-three clinical strains of Sporothrix were identified by partial sequencing of the calmodulin gene. An antifungal susceptibility test of amphotericin B, terbinafine, itraconazole, posaconazole and isavuconazole was performed according to the broth microdilution method. Most patients were male (55.8%). Regarding the source of infection, 21 patients (48.8%) reported trauma involving plants and/or contact with soil. Sporothrix brasiliensis was the predominant species (n = 39), followed by S. globosa (n = 3) and S. schenckii (n = 1). Sporothrix brasiliensis was associated with all the sources of infection, reinforcing previous data showing the presence of this species in environmental sources, as well as with all the clinical forms, including severe cases. One clinical strain of Sporothrix brasiliensis was classified as a non-wild-type strain for amphotericin B and another for itraconazole. S. schenckii was classified as non-WT for all the antifungals tested. In this context, it is important to emphasize that non-zoonotic sporotrichosis still occurs in the state of Rio de Janeiro, with S. brasiliensis as the main etiological agent, primarily associated with infections acquired after traumatic inoculation with plants and/or soil contact, followed by S. globosa and S. schenckii. In addition, non-WT strains were found, indicating the need to monitor the antifungal susceptibility profile of these species. It is crucial to investigate other natural sources of S. brasiliensis to better understand this fungal pathogen and its environment and host cycle.